Drug Trial News

RSS

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Study finds broader statin use as a cost-effective way to prevent heart attack and stroke

A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke. The Stanford University School of Medicine study also found that using a popular test - a screening for high sensitivity C-reactive protein, or CRP - to identify patients who may benefit from statin therapy would be cost-effective, but only under certain scenarios.

29 Sep 2010

Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model

GlycoMimetics, Inc., a clinical stage biotechnology company developing a new class of glycobiology based therapies for a broad range of indications, today announced that the journal Blood has published pre-clinical data on the company's lead compound GMI-1070 in a model of sickle cell disease.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%-72% as compared with placebo.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Further trials needed to determine clinical application of Abatacept in SLE

Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063.

28 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

GenMark’s eSensor technology selected for Warfarin clinical study

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, announced today that their eSensor Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study the WARFARIN Trial.

28 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.

28 Sep 2010

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

28 Sep 2010

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.

27 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

Drug Trial News

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Study finds broader statin use as a cost-effective way to prevent heart attack and stroke

Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Further trials needed to determine clinical application of Abatacept in SLE

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

GenMark’s eSensor technology selected for Warfarin clinical study

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News